Abstract
Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1314-1321 |
| Number of pages | 8 |
| Journal | Journal of the American Academy of Child and Adolescent Psychiatry |
| Volume | 35 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jan 1 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- attention deficit disorder with hyperactivity
- attention- deficit hyperactivity disorder
- bupropion
ASJC Scopus subject areas
- Developmental and Educational Psychology
- Psychiatry and Mental health
Cite this
Bupropion hydrochloride in attention deficit disorder with hyperactivity. / Conners, C. Keith; Casat, Charles D.; Gualtieri, C. Thomas; Weller, Elizabeth; Reader, Mark; Reiss, Allan; Weller, Ronald A.; Khayrallah, Moise; Ascher, John.
In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 35, No. 10, 01.01.1996, p. 1314-1321.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bupropion hydrochloride in attention deficit disorder with hyperactivity
AU - Conners, C. Keith
AU - Casat, Charles D.
AU - Gualtieri, C. Thomas
AU - Weller, Elizabeth
AU - Reader, Mark
AU - Reiss, Allan
AU - Weller, Ronald A.
AU - Khayrallah, Moise
AU - Ascher, John
PY - 1996/1/1
Y1 - 1996/1/1
N2 - Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.
AB - Objective: This is a multisite, double-blind, placebo-controlled trial to determine the safety and efficacy of bupropion in the treatment of children with attention deficit disorder with hyperactivity (ADDH). Method: In a four-center, double-blind comparison of bupropion (n = 72) and placebo (n = 37), children aged 6 to 12 years meeting DSM-III criteria for ADDH were randomized to receive bupropion 3 to 6 mg/kg per day or placebo, administered twice daily, at 7 A.M. and 7 P.M. Measures of efficacy included the Conners Parent and Teacher Questionnaires (93-item, 39-item, and 10-item), Clinical Global Impressions Scales of Severity and Improvement, the Sternberg Short- Term Memory Task, and the Continuous Performance Test Screen and posttreatment physical examinations, electrocardiograms, electroencephalograms, and clinical laboratory evaluations were performed. Height, weight, and vital signs were measured and adverse experiences were assessed weekly. Results: A significant treatment effect, apparent as early as day 3, was present for both conduct problems and hyperactivity on the Conners 10-item and 30-item teacher's checklist, and at day 28 for conduct problems and restless-impulsive behavior on the 93-item parent questionnaire. Findings were of smaller magnitude for parent ratings than teacher ratings. Significant treatment effects were present on both the Continuous Performance Test and memory retrieval test. Effect sizes of bupropion/placebo differences for teacher and parent ratings in this study were somewhat smaller than for standard stimulant drugs used to treat ADDH. Bupropion appeared to be well tolerated in most children. Dermatological reactions were twice as frequent in the drug group as the placebo group, with four reactions involving rash and urticaria that were serious enough to require discontinuation of medication. Conclusions: Bupropion may be a useful addition to available treatments for ADDH. Comparative trials with such standard drugs as methylphenidate are warranted to determine the relative clinical merits of bupropion.
KW - attention deficit disorder with hyperactivity
KW - attention- deficit hyperactivity disorder
KW - bupropion
UR - http://www.scopus.com/inward/record.url?scp=0029819433&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029819433&partnerID=8YFLogxK
U2 - 10.1097/00004583-199610000-00018
DO - 10.1097/00004583-199610000-00018
M3 - Article
C2 - 8885585
AN - SCOPUS:0029819433
VL - 35
SP - 1314
EP - 1321
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
SN - 0890-8567
IS - 10
ER -